CureZone   Log On   Join
Re: Why push the H1N1 vaccine so hard?
 
Exploited Citizen Views: 1,468
Published: 9 years ago
 
This is a reply to # 1,708,325

Re: Why push the H1N1 vaccine so hard?


Said vaccine, H1N1, is a covert sterilization campaign to reduce birth rates globally.
The shot permanently sterilizes you using the same technology contained in the WIPO patents outlined below.



Squalene emulsified in Tween 80 is used in swine-flu vaccine as an adjuvant according to Norvatis patent, also used as immunization-sterility vaccine for domestic animals according to Ohio State patent.
Norvatis is the pharmaceutical company which is producing swine-flu vaccine for western countries and the vaccination will begin this fall, ONLY on young peoples including school children and pregnant mothers.
Population control?

SQUALENE EMULSIFIED IN TWEEN 80 SURFACTANT USED AS IMMUNIZATION –STERILITY VACCINE ON DOMESTIC ANIMALS:http://www.wipo.int/pctdb/en/wo.jsp?WO=1984003443&IA=US1983000777&DISPLAY=DESC
WIPO Patent Application WO/1984/003443 Kind Code:A1
Modified polypetides capable of provoking the formation of antibodies in an animal may be produced by forming a linear polymer of polypeptide fragments, each having a molecular structure similar to a fragment of the protein to which antibodies are to be provoked. Such linear polymers can be made more immunogenic than the proteins to which they are related without introducing undesirable extraneous materials into the animal being treated, but have reproducable immunogenic properties. Proteins which are not endogenous or immunogenic to an animal can be chemically modified so as to make them more immunogenic. Also, modified antigens useful for fertility control can be produced by chemical modification of zona pellucida or sperm antigens. These modified polypeptides, antigens and modified antigens are desirably administered in the form of a vaccine having a vehicle comprising a mixture of mannide monooleate with Squalene and/or Squalene.

(Note: Tween 80 is a mannide oleate)

Original Provisional Patent:
FAYRER-HOSKEN, Richard, A. [US/US]; (US) (US Only). Inventor:FAYRER-HOSKEN, Richard, A.; (US). Agent:SANDBERG, Victoria, A.; Mueting, Raasch & Gebhardt P.O. Box 581415 Minneapolis, MN 55458-1415 (US). Priority Data:
60/070,375 02.01.1998 US
60/071,406 15.01.1998 US
60/076,368 27.02.1998 US
Title: FERTILITY IMPAIRING VACCINE AND METHOD OF USE Abstract: A vaccine comprising an antigen derived from a zona pellucida glycoprotein is effective to impair fertility in animals, preferably carnivores. The vaccine can be used as an immunosterilant or an immunocontraceptive.FERTILITY IMPAIRING VACCINE AND METHOD OF USE This application claims the benefit of U. S. Provisional Application No. 60/070,375, filed January 2,1998, U. S. Provisional Application No. 60/071,406, filed January 15,1998, and U. S. Provisional Application No.
60/076,368, filed February 27,1998.

SQUALENE EMULSIFIED IN TWEEN 80 SURFACTANT USED AS ADJUVANT FOR SWINE-FLU VACCINE:http://www.freepatentsonline.com/y2009/0208523.html (Norvatis ‘s patent)
Title:Adjuvant for vaccines
Document Type and Number:United States Patent Application 20090208523
Kind Code:A1

Abstract:
Vaccine containing a first vaccine, adjuvated with an oil-in-water emulsion comprising 5% squalene, 0.5% polysorbate 80 and 0.5% sorbitan trioleate in aqueous citrate buffer pH 6.5, and a nonadjuvated second vaccine as combination partners for the simultaneous, separate or phased application for immunization against viral, bacterial or parasitic infectious diseases.
Inventors:Broeker, Michael (Marburg, DE)
Application Number:12/386753
Publication Date:08/20/2009
Filing Date:04/22/2009
Attorney, Agent or Firm:
NOVARTIS VACCINES AND DIAGNOSTICS INC. (INTELLECTUAL PROPERTY- X100B, P.O. BOX 8097, Emeryville, CA, 94662-8097, US)

Claims:
1. A method for the contralateral administration of more than one vaccine composition, said method comprising: (1) administering a first vaccine composition comprising a selected antigen and MF59 to a subject; and (2) administering a second vaccine composition contralaterally to the subject, wherein said second vaccine composition comprises a selected antigen and does not include MF59.
(Note: MF-59 consists of 5% squalene, 0.5% polysorbate Tween 80, as described in the patent abstract.)
 

 
Printer-friendly version of this page Email this message to a friend
Alert Moderators
Report Spam or bad message  Alert Moderators on This GOOD Message

This Forum message belongs to a larger discussion thread. See the complete thread below. You can reply to this message!


 

Donate to CureZone


CureZone Newsletter is distributed in partnership with https://www.netatlantic.com


Contact Us - Advertise - Stats

Copyright 1999 - 2019  www.curezone.org

0.390 sec, (2)